Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV-1106 vs Somatropin in Pediatric Growth Hormone Deficiency
NCT02092077Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of albusomatropin in growth hormone deficiency (GHD) (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Height velocity at 6 months. Started Apr 2014; status: terminated.
02
Drugs
albusomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02092077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092077.